Skip to main content

New, free course on capturing the value of V1C for healthcare!

Join FDA and DiMe during a 2-day virtual event.

Statistical considerations for successful digital health innovation


August 26, 2021

Discussion Topic

Why should you report your modeling plan or statistical analysis plan before seeing any data? Why should we all ditch the term ‘statistical significance’ but keep statistical evidence? And how? A fantastic discussion with Eric Daza, Lead Statistician for Digital Health Outcomes at Evidation Health, as he dives into key themes from his recent pieces: Artifice or intelligence? and Ditch ‘statistical significance’.

Our conversation explored two proposed research changes for our field: 1) Splitting all gathered data into a small number of random subsamples to test reproducibility/replicability of results; 2) For exploratory analyses, continue to report CI’s and p-values—but explicitly state as possible uncertainty to expect using new data.

Listen to the recording

View the presentation slides

Join our next project

Help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients

Join the Integrated Evidence Plans project

Join us
Not today